Last reviewed · How we verify
NCT06834321
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
Phase 2 trial testing Homoharringtonine combined with androgen deprivation therapy in Prostate CA in 96 participants. Currently enrolling.
28 September 2026
Quick facts
| Lead sponsor | baotai Liang |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 96 |
| Start date | 19 March 2025 |
| Primary completion | 28 September 2026 |
| Estimated completion | 28 September 2027 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Homoharringtonine combined with androgen deprivation therapy — full drug profile →
- Placebo combined with androgen deprivation treatment group — full drug profile →
- radical prostatectomy
Conditions studied
- Prostate CA — all drugs for Prostate CA →
Sponsor
baotai Liang — full company profile →
Who can join
Adults 18 to 85, male only, with Prostate CA. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although neoadjuvant androgen deprivation therapy combined with radical prostatectomy reduced the positive rate of surgical margins, it did not show statistically significant improvement in prostate-specific antigen (PSA). At the same time, few trials reported pathological complete response (pCR) and minimal residual lesion (MRD). The purpose of this project is to verify the therapeutic effect of homoharringtonine combined androgen deprivation in patients with locally advanced prostate cancer or oligometastatic prostate cancer before radical prostatectomy through a randomized controlled clinical trial, so as to find an effective treatment for locally advanced prostate cancer or oligometastatic prostate cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A conserved eIF1A<sup>+</sup> luminal cell-centered hypoxic and "cold" tumor microenvironment promotes pan-subtype prostate cancer progression.
Cheng Y, Wan L, Huang E, Zheng B, et al · · 2026 · PMID 41707646 · DOI 10.1016/j.xcrm.2026.102619
Verify or expand the search:
- PubMed search for NCT06834321
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate CA
Currently open trials in the same condition.
- NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting
- NCT06904313 — Ultralow Dose PET Imaging for PSMA Expression · Phase 2 · recruiting
- NCT06612034 — Prostate Cancer Care Disparity Analysis Project (ProGAP) · recruiting
- NCT06861192 — Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of P · Phase 2, PHASE3 · recruiting
- NCT06748742 — A Randomized Controlled Trial to Improve the Therapeutic Effect of Robot-assisted Radical Prostatectomy (RARP) Using Ind · active not recruiting
Other baotai Liang trials
Trials by the same sponsor.
- NCT07163910 — Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinic · Phase 2 · recruiting
- NCT06861166 — Clinical Study of Geranium Wilfordii Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer · Phase 2, PHASE3 · not yet recruiting
- NCT06861192 — Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of P · Phase 2, PHASE3 · recruiting
- NCT07250542 — A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Met · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06834321 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by baotai Liang
- Last refreshed: 8 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06834321.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing